STAT3 ORF cDNA Lentivirus

Background

STAT3 (Signal Transducer and Activator of Transcription 3) is a latent cytoplasmic transcription factor activated downstream of cytokine and growth factor receptors through the JAK/STAT pathway. Upon tyrosine phosphorylation, STAT3 dimerizes, translocates to the nucleus, and activates genes controlling cell proliferation, survival, differentiation, angiogenesis, and inflammation. STAT3C is an engineered, constitutively active variant that dimerizes independent of upstream cytokine signaling. STAT3 is frequently hyperactivated in human cancers, where it promotes tumor growth and immune evasion, making both wild-type STAT3 and the STAT3C mutant valuable tools for dissecting JAK/STAT signaling and its role in oncogenesis and inflammation.

Product Description & Applications

This ORF cDNA lentivirus enables stable overexpression of human STAT3, available in both wild-type form and the constitutively active STAT3C variant. Expression is driven by a CMV promoter, and each construct may include an epitope tag, a fluorescent reporter such as GFP or RFP, and an antibiotic selection marker, with elements fused or linked by self-cleaving peptide sequences depending on the configuration.

Delivered as a third-generation, VSV-G-pseudotyped system, the PEG- and sucrose-gradient-purified particles transduce a wide range of cells, including primary and thawed cultures, and support establishment of long-term stable lines by antibiotic selection or FACS. The paired wild-type and constitutively active constructs support research on JAK/STAT signaling, cell proliferation and survival, and STAT3-driven oncogenesis.

About This Product

This ORF cDNA lentivirus enables stable overexpression of STAT3, STAT3C (NCBI Accession: NM_139276) in mammalian cells via a third-generation, VSV-G pseudotyped delivery system. The ORF cDNA is fused to a C-terminal epitope tag (V5, Myc, or HA) and expressed under a strong constitutive promoter (CMV). Reporter and selection marker components (EGFP, mCherry, GFP, RFP; Blasticidin, Puromycin) are co-expressed via self-cleaving P2A peptides, enabling independent protein production without fusion-tag artifacts.

Ultra-purification by PEG precipitation and sucrose gradient centrifugation yields high-titer particles suitable for primary cells, suspension cultures, and stem cells. Stable polyclonal cell lines are established within 10–14 days by antibiotic selection or FACS sorting. For in vivo applications, the serum-free formulation and VSV-G envelope support direct administration or further concentration for stereotactic injection.